Denali Capital Acquisition Corp. Class A (DECA) has shared an announcement.
Denali Capital Acquisition Corp. has entered into a merger agreement with Semnur Pharmaceuticals, which will result in Semnur becoming a wholly owned subsidiary of Denali. This all-stock transaction is valued at $2.5 billion, with Semnur’s equityholders receiving shares in the new combined entity, which will be renamed Semnur Pharmaceuticals, Inc. The deal, which includes customary representations, warranties, and covenants, is expected to close by the first quarter of 2025, subject to approval by Denali’s shareholders and other closing conditions. The merger aims to create a more robust financial platform for growth and shareholder value in the pharmaceutical industry.
Learn more about DECA stock on TipRanks’ Stock Analysis page.
